LBO Pitch on Acadia Healthcare (NASDAQ: ACHC)

The Pitch

Company Background - Acadia is the largest stand-alone behavioral health operator in the U.S., providing a full continuum of care to 84,000 daily patients across 277 facilities, 12,500 beds, and 40 states through four service lines: acute inpatient psychiatric hospitals (53% of revenue, 7–10 day average stay), specialty addiction treatment facilities (19%, 30–90 days), comprehensive treatment centers (CTCs) for opioid use disorder (17%, indefinite stay), and residential treatment centers for psychiatric care (11%, 3+ months). Acadia generated $3.3bn in revenue and $608.9mm in adj. EBITDA (18.4% margin) in FY25, with a heavy concentration in Appalachia and the Mid-Atlantic (41% of total facilities).

Acadia operates in the $97bn U.S. behavioral health market, growing at a 6.4% CAGR. The industry is inherently local: legislation (like the presence of IMD 1115 waivers and CON laws, discussed below) and Medicaid reimbursement rates differ by state. In-network referrals (cross-selling across service lines) and regional joint venture partnerships (JVs) are crucial to patient inflow. Acadia and UHS, another leading behavioral health services provider, collectively possess ~11% of the market, with the top 10 providers representing under 20% of total revenue. This underscores the industry's fragmentation and consolidation opportunity, particularly in Acadia's higher-margin non-anchor businesses (specialty, CTCs, and residential). Acadia’s closest competitors are UHS ($6.8bn behavioral health revenue, 331 facilities) and BHG ($265–500mm revenue, 117 facilities).

Executive Summary - Acadia trades at 7.7x LTM adj. EBITDA, well below its 11.0x 10Y average due to self-inflicted missteps and external headwinds. One such headwind is litigation for holding patients beyond medical necessity, with NYT investigative pieces triggering government scrutiny. Management compounded this damage by paying the entire $394mm legal fee at once instead of appealing verdicts (UHS successfully reduced a $535mm jury award to $180mm). Management's “growth-at-all-costs” (GAAC) capital allocation strategy has been the primary driver of value destruction, contributing to -71.1% TSR over the past two years and short interest nearing 30%, capping a decade of self-inflicted underperformance that the market has dubbed the "lost decade." While litigation risk is inherent to the industry, GAAC is the root cause of underperformance. Inefficient uses of capital have been common: over 70% of new beds in FY25 were deployed into lower-ROI de novo facilities, where Acadia benchmarks a mere 20% return vs. UHS's 30%. This crowds out higher-ROI alternatives like bed expansions at existing facilities and potential growth via CTC construction and JV partnerships. We believe overly-aggressive de novo capex has obscured Acadia’s intact fundamentals and strong underlying FCF profile, with growth capex running at ~15% of revenue since FY22, vs. ~3% for maintenance capex. Externally, the One Big Beautiful Bill Act (OBBBA) has created reimbursement uncertainty as the federal government targets Medicaid spending reductions. Furthermore, Acadia’s corporate management structure was reorganized in 2022 from a model where mid and upper-level managers monitored facilities in a given geographic area to one where managers monitored facilities based on service line, neglecting the fundamentally local nature of behavioral health.

Public statements by activists Engine Capital and Khrom Capital are heightening the urgency for a sale. A buyout creates value for this noncyclical, entrenched, and well-capitalized business by (1) reverting to geographically-organized management and redirecting leadership’s incentives, (2) further optimizing the facility portfolio by divesting underperforming and geographically-unfavorable acute inpatient locations, and (3) redirecting growth capex away from de novos towards incremental beds at existing facilities, allowing the firm to harness Acadia’s growth potential and right management’s missteps.

Investment Merits - The firm can capitalize on several merits simply by purchasing the asset. Acadia operates in a noncyclical, high-barrier industry with structural and growing demand – suicide deaths rose 33% between 2009 and 2023, opioid incidence remains elevated despite broader Narcan availability, and Acadia's CFO has confirmed no near-term demand deterioration. Furthermore, Acadia is entrenched in local healthcare environments, a competitive advantage over new entrants who must develop local government relationships and overcome communal “NIMBY” (not in my backyard) sentiment and lengthy state “CON” (certificate of need) processes. CONs require hearings to grow facilities beyond 10% in a year. Moreover, the structural bed shortage throughout the psychiatric care industry, due to the Community Mental Health Act (1963) and IMD legislation, shows no signs of abating. Additionally, even though the extensive 2023–2025 de novo buildout was a grossly inefficient use of capital given the aforementioned higher-ROI alternatives, the new facilities will begin converting to profitability as new beds ramp toward stabilized occupancy. Startup losses of $60–65mm are expected to flip, capex will drop ~$230mm by FY27, and FCF is expected to turn positive. This leads to an added $900mm+ in cash generation over a five year window without any new top-line acceleration.

Value Creation Plan 1: Restore organizational accountability by reverting back to a geographically-organized management model and recalibrating company leadership - In 2022, management undertook a reorganization of the company’s reporting structure, shifting from a geographically-organized model to one based on service lines. This diverges from the fundamentally local nature of behavioral health – 50% of revenue flows through local managed care organizations (MCOs). This switch sacrificed regional presidents’ priceless knowledge of their local markets, resulting in same-facility growth decelerating from 9.2% to 4.4% between FY22 and FY25. This structure has also resulted in bloated bureaucracy throughout the company – between 2022 and 2025, corporate office costs per facility rose 29%. Moreover, this organizational change stunted cross-selling and patient volume growth due to the elimination of regional managers' incentives to encourage in-network referrals, as performance evaluation shifted to service line P&L alone. Suspiciously, the company provides no disclosure around cross-selling activity, in-network referral rates, or CACs, raising concern over the value destruction caused by this change (as per our research and Engine Capital’s Letter to the Board). A switch back to the geographical management model will help Acadia maximize its in-network referrals, reducing CACs and keeping patients in-network.

Additionally, management and the board must be replaced (Debra Osteen is the current interim CEO) and reincentivized. The new incentive structure should shift from the adj. EBITDA and revenue framework, which rewards de novo capex over returns, to ROIC improvement and relative TSR metrics. As of now, management can underperform all peers by a wide margin and still earn 75% of its long-term incentives if growth metrics are hit. This GAAC-encouraging compensation structure led to the inefficient deployment of ~$1bn on de novo facilities in the past four years. Furthermore, insider ownership is less than 2% compared to UHS’ 14%, despite having a market cap ~6x smaller. Beyond finding a long-term CEO, the board must be repopulated with fresh faces who have deep behavioral health operating experience. Of the 10-person board, only one has relevant operational experience. Additionally, five members have served over nine years, surpassing the recommended timeframe by proxy advisors and institutional investors. A corporate governance constitution must be instituted to limit the tenure of board members and ensure that leadership incentives align with shareholder value creation.

Value Creation Plan 2: Optimize the portfolio by divesting underperforming and geographically-challenged acute inpatient facilities and selectively pursuing sale-leasebacks - Due to the aforementioned inefficient capital allocation, Acadia has multiple underperforming and isolated acute inpatient facilities in harsh regulatory geographies. Isolated facilities in areas with insufficient network density are far more likely to underperform given the inherent inability for in-network referrals. Selling off some (or all) of these assets would provide additional cash for the firm to pay down debt, improve EBITDA, and invest in higher-ROIC initiatives in favorable geographies. One such candidate is Montrose Behavioral Health Hospital (IL), which after four years of operation, runs at only 40% occupancy across 161 beds, generates revenue per bed of only $456k (against $728k Acadia average) and posts a -17% profit margin. These operational failures are compounded due to state regulation: Illinois lacks an approved IMD 1115 waiver, and with no other Acadia facilities statewide, there is insufficient network density to drive cross-referrals. This facility is a financial and operational burden to Acadia, alongside seven additional divestiture candidates that exhibit comparable operational and regulatory deficiencies across its network. Potential buyers of these assets include other behavioral health operators (such as Oceans Healthcare or Haven Behavioral Health), large hospital systems with sizable inpatient behavioral footprints, regional hospitals, and financial sponsors. The 180 strategic acquisitions that took place across the behavioral health space in 2025 signal an active buyer universe that would support a competitive sale process for these assets. Regional operators with denser local networks stand to realize value from acquiring Acadia’s underperforming facilities due to greater cross-selling opportunities. Given the unforgiving conditions that these facilities operate under, precedent strategic transactions have occurred at 0.9x–2.5x revenue for profitable facilities, and at sub-1.0x for unprofitable facilities. The strained nature of these assets compels other types of buyers to pay similar multiples. Exiting these eight facilities would provide $376mm in FCF, leaving the firm with a leaner, higher-quality platform for an eventual IPO. However, due to GAAC incentives, management is unwilling to consider divestitures, with Osteen noting on the most recent earnings call: “We're not talking about closures at this point and don't anticipate being in that situation,” despite having $750mm+ in tax credits that could be used to offset capital gains.

In parallel, Acadia can unlock non-core capital through sale-leasebacks of owned real estate tied to its higher-performing facilities. While a conservative land-only approach generates ~$180mm of proceeds, leasebacks on buildings and equipment represent unmodeled upside of up to 5x land proceeds, providing liquidity to accelerate deleveraging and reinvestment into higher-ROIC initiatives.

Value Creation Plan 3: Rationalize growth capex by prioritizing lower risk, higher reward incremental bed expansions over de novo acute inpatient facilities - Ground-up hospital builds carry lower returns and higher risk than expanding existing facilities. Acadia has added 1,535 beds (out of 2,460 total) through de novo acute inpatient facilities over the past three years. Across the industry, de novo construction costs are significantly higher than adding beds to existing facilities. Furthermore, de novos require lengthy CON processes, take up to five years to stabilize, must hire staff before admitting patients, and cannot bill Medicare or Medicaid until receiving a provider number, which requires active patients on-site. Due to these factors, de novos operate at losses for 3-6 months before any revenue is collected, which resulted in $58mm in startup losses in FY25. In contrast, expanding bed count at existing facilities creates operating leverage by requiring only clinical hires at the margin, preserving uninterrupted Medicare billing, capitalizing on existing customer bases, and benefiting from shared overhead. Incremental beds have ~40% EBITDA margins, compared to the industry average of ~15% stabilized EBITDA margins for de novos. Osteen described bed expansions at existing facilities as "the best use of [Acadia’s] capital." Despite this, the company has deployed $1bn+ in de novo capex since 2022 with deteriorating margin guidance and zero cohort-level disclosure on new-builds, suggesting subpar returns.

To achieve higher-ROI growth, Acadia can expand beds at existing facilities running above 80% occupancy (the industry threshold for full capacity), particularly in favorable IMD 1115 waiver states. The IMD Exclusion Act prohibits federal Medicaid from funding mental disease care in facilities with more than 16 beds. However, IMD 1115 waivers allow states to receive federal Medicaid-matched funding for short-term stays of less than 30 days. 17 states have approved waivers and 4 states are pending approval. Using alternative data from the American Hospital Directory, we have isolated 9 existing Acadia facilities operating above 80% occupancy in these geographies, implying sufficient demand to support immediate expansion. Expanding existing facilities requires simpler CON processes given less competitor objection and proven market demand. Moreover, analysis of public record Tennessee CON filings reveal a material cost differential between ground-up facility development and incremental bed additions within Acadia’s own portfolio: de novo construction averaged ~$379k per bed, compared to ~$24k per incremental bed expansion requiring minor construction and ~$22k where no construction was needed at all (non-Acadia operators show the same pattern). Combined with the aforementioned revenue advantages of bed additions, this cost difference implies payback periods of weeks rather than years and astronomically higher ROIs for incremental bed expansion projects. According to management, the average Acadia facility can expand by 40 beds. A base-case 40-bed expansion across the 9 targeted facilities would produce an additional $115mm+ in adj. EBITDA annually, all while reducing growth capex by ~$230mm annually (~8.9% revenue), relative to continued de novo construction. A pipeline for these opportunities exists: we have identified five recently-built facilities still ramping in favorable states with potential for expansion upon stabilization.

Beyond incremental bed expansions, Acadia's JV program and CTC segment represent additional pathways for capital-light growth (relative to de novos). The JV program (currently 21 ventures) remains underleveraged by management. In a JV arrangement, Acadia is the operating partner and shares 50% of revenues and costs alongside a hospital system partner. JVs offer existing referral networks, resulting in faster fill rates, lower startup costs, and exclusivity agreements that permanently block UHS, Lifepoint, and other competitors from the referral corridor. We model a $1.9bn revenue uplift by FY30 assuming continuation of the historical ~2 new JVs per year. Furthermore, Acadia's existing network of CTCs remains geographically concentrated, and targeted expansion into whitespace markets where Acadia already holds inpatient licenses would add a recurring, low-acuity revenue stream with minimal incremental fixed cost.

Risks - First, NIMBY risk: NIMBY opposition triggers construction disputes that lead to average cost overruns of 33.2% and schedule extensions of 66.5%. Applied to a standard $65mm Acadia de novo, this implies $21.6mm in excess project costs and timelines extending from 18–24 to 30–40 months, pushing stabilization from 3–5 to 5–7 years. CON laws in 35 states formalize this risk, giving a single objector the ability to delay a multi-year capital commitment indefinitely. Our theses neutralize Acadia’s primary exposures to this risk: bed expansion at existing facilities eliminates new approval requirements and reinstating geographic management enables pre-permit stakeholder engagement. JV structures provide institutional shielding unavailable to standalone operators (Henry Ford's Detroit JV secured $604mm in community benefits agreements, including rezoning approvals). The empirical basis for opposition may also be overstated, as property values increased post-opening in 7 of 9 Philadelphia facilities studied, with a Seattle difference-in-difference model finding no causal effect.

Second, reimbursement risk: Although reimbursement uncertainty is a hallmark of the behavioral health industry, the passage of the OBBBA has materially elevated this risk by reducing federal Medicaid contributions and increasing fiscal burden on states, which may prompt states to limit covered services. Acadia is particularly exposed to this: 58% of its revenue is Medicaid-derived compared to ~40% for behavioral health peers. Because reimbursement rate cuts flow entirely through to providers regardless of the federal/state cost-sharing split, state-level budget pressure represents a notable revenue headwind. To mitigate this, Acadia should contract with an RCM provider to bolster revenue and cash flow through backend solutions (claim submission, payment processing, denial review) and frontend solutions (payment eligibility review), delivered via AI, automation, and RCM experts. From published case study data, a partnership can deliver a 93% improvement in first-claim pay ratio, 44% reduction in charge entry lag, and 41% reduction in primary adjudication lag, bringing material benefits to Acadia's charge capture process.

Deal Financing, Structure, & Exit Strategy - We model a base-case buyout at a 30% control premium to 3/29/2026 share price, financed at a 35.9% loan-to-value across four tranches: an undrawn Revolver, TLA (S+400), TLB (S+450), and PIK Toggle Notes (10.25% cash/11.75% PIK). Term loan pricing is benchmarked to the most recent quarter’s BSL spread of S+384 bps on LBO transactions. The PIK toggle preserves liquidity during periods of elevated legal spend without pressuring covenant headroom. The equity check includes all of management’s $35mm in equity, directly aligning leadership with our value creation agenda from day one. The $203mm legal reserve escrow provides downside protection against the active DOJ investigation and pending litigation. We target an IPO exit at year five, by which point Acadia will have rationalized capex, converted startup losses to profitability, and demonstrated a sustained FCF inflection. Further avenues for growth post-IPO will include continued investments in incremental beds, JVs, and CTC facilities (via roll-ups and de novos), along with prudent acute inpatient de novo initiatives (in a cautious, low risk, capital-efficient fashion). This presents a clean story for the public market to re-rate toward historical multiples. A conservative 8.3x exit multiple (no expansion), below the 12.0x historical average and 11.0x–13.0x industry range, generates a 23% IRR and 2.8x MOIC at base. Bear case IRR is ~8% and bull case IRR is ~33%. Should public markets be unfavorable, a Lifepoint-Acadia combination under joint-PE sponsorship or a strategic acquisition by a large health system seeking behavioral health capacity are possible exit paths.

Post-Mortem & Reflection

Coming soon